Compare Stitch Fix Inc (SFIX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs TG Therapeutics Inc — how do they compare? Stitch Fix Inc trades at $2.83 (market cap $366.07M), while TG Therapeutics Inc trades at $54.83 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 22.3× Stitch Fix Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Stitch Fix Inc for 31 Days and TG Therapeutics Inc for 16 Days on average.
| SFIX | TGTX | |
|---|---|---|
Market Cap | $366.07M | $8.16B |
Volume | 5,152,008 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.64 | $59.06 |
52-Week Low | $2.16 | $26.94 |
Typical Hold Time | 31 Days | 16 Days |
Enterprise Value | $261.88M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $2.775, up 1.65% on the day, but faces a bearish technical outlook with recent earnings beats overshadowed by weak forward guidance. The company reported a net loss of $28.74 million for 2025, though losses have narrowed significantly from prior years. Revenue remains stable at $1.27 billion, but negative cash flow and multiple law firm investigations into potential fraud create headwinds.
The investment outlook is cautious. While valuation appears cheap on a P/S basis and AI initiatives show promise, declining active clients, negative profitability metrics, and bearish analyst sentiment limit upside. The primary risk is execution against a challenging consumer backdrop, with the stock's trajectory hinging on a sustainable turnaround in client growth and margins.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
